drugset / Trial / NCT06772792

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)

NCT06772792

Phase 1 Completed 36 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelBasic science

Summary

The goal of this study is to learn what happens to a single dose of alendronate over time in a healthy participant's body when the participant is given a single dose of enlicitide decanoate. Researchers want to learn how safe and tolerable is the co-administration of enlicitide decanoate and alendronate.

Timeline

Start
2024-04-23
Primary completion
2024-06-21
Completion
2024-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule Oral
Subject Enlicitide Decanoate Unknown Oral

Indications

No indication recorded.